Takeda Pharmaceutical Company Limited

Yasuko Horikoshi

Hirokazu Matsumoto

Tetsuya Ohtaki

Chieko Kitada

Yasushi Masuda

The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically reacting with a partial peptide at the N-terminus or C-terminus of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or its derivative, and a method of detecting/quantifying metastin or its derivative using the antibody as well as a diagnostic agent using the same.

Anti-metastin antibody and its use

The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.

ZAQ ligand-1 antibodies and uses thereof

The present invention intends to provide a novel monoclonal antibody having a binding specificity to GALP or its derivative, which is useful in developing therapeutic agents, preventive agents or diagnostic agent for diseases associated with GALP or its derivative, and a method of quantifying GALP using the antibody. More specifically, the present invention provides an antibody specifically reacting with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or its derivative, and a method of quantifying GALP or its derivative.

Growing community of inventors

Ibaraki, Japan

Yasuko Horikoshi